INmune Bio Advances Regulatory Pathways for CORDStrom and XPro Amid Cost-Cutting
Event summary
- INmune Bio completed a pre-submission package with the UK MHRA for CORDStrom in RDEB, targeting mid-summer MAA filing.
- Signed an expanded agreement with Anthony Nolan for long-term umbilical cord tissue supply for CORDStrom.
- Reported new Phase 2 imaging data for XPro in early Alzheimer's Disease at CTAD conference.
- Q1 2026 net loss narrowed to $5.4M from $9.7M YoY, with R&D expenses down 52% to $3.6M.
The big picture
INmune Bio is strategically positioning its CORDStrom and XPro platforms for regulatory approvals while demonstrating fiscal discipline. The company's ability to secure long-term supply agreements and present clinical data at major conferences underscores its focus on execution amid a competitive immunology landscape. The narrowing of net losses suggests operational improvements, but the path to profitability remains contingent on successful regulatory outcomes and clinical validation.
What we're watching
- Regulatory Momentum
- Whether INmune Bio can successfully navigate the UK MHRA, EMA, and FDA regulatory pathways for CORDStrom by year-end.
- Cost Efficiency
- The sustainability of INmune Bio's reduced R&D spend while advancing multiple clinical programs.
- Clinical Validation
- The impact of upcoming XPro imaging data on the adaptive Phase 2b/3 registrational pathway alignment with FDA.
Related topics